Simply walking around counts
de la Pea A, Seger M, Soon D, et al
People who are prescribed semaglutide the active ingredient in Ozempic and Wegovy as a treatment for type 2 diabetes may have a reduced risk of Alzheimers disease, according to a new study published in the scientific journal Alzheimers & Dementia
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists in persons with obesity and knee osteoarthritis in this population has not been well-established. To test the impact of a GLP-1 receptor weight loss medication on knee OA outcomes, Bliddal and colleagues conducted a double-blind, randomized, placebo-controlled trial at 61 sites across 11 countries
Semaglutide has gained popularity both online and offline
Dyslipidemia : Wegovy helps improve cholesterol levels, reducing LDL (bad cholesterol) and increasing HDL (good cholesterol)